ISL + FTC/TDF + FTC/TAF + Placebo to ISL + Placebo to FTC/TDF + Placebo to FTC/TAF
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Preexposure Prophylaxis
Conditions
HIV Preexposure Prophylaxis
Trial Timeline
Mar 15, 2021 → Aug 4, 2023
NCT ID
NCT04652700About ISL + FTC/TDF + FTC/TAF + Placebo to ISL + Placebo to FTC/TDF + Placebo to FTC/TAF
ISL + FTC/TDF + FTC/TAF + Placebo to ISL + Placebo to FTC/TDF + Placebo to FTC/TAF is a phase 3 stage product being developed by Merck for HIV Preexposure Prophylaxis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04652700. Target conditions include HIV Preexposure Prophylaxis.
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04652700 | Phase 3 | Terminated |